May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Effect of CS-088, an Angiotensin AT1 Receptor Antagonist, on Intraocular Pressure (IOP) in Glaucomatous Monkey Eyes
Author Affiliations & Notes
  • R. Wang
    Ophthalmology, Mt Sinai School of Medicine, New York, NY, United States
  • T.W. Mittag
    Ophthalmology, Mt Sinai School of Medicine, New York, NY, United States
  • S.M. Podos
    Ophthalmology, Mt Sinai School of Medicine, New York, NY, United States
  • T. Yokoyama
    Pharmacology and Molecular Biology Research Laboratories, Sankyo Co. Ltd., Tokyo, Japan
  • Footnotes
    Commercial Relationships  R. Wang, None; T.W. Mittag, None; S.M. Podos, Alcon Lab F, C; T. Yokoyama, Sankyo Co. Ltd. E.
  • Footnotes
    Support  NIH grant EY 01867 and unrestricted grant from RPB, and Sankyo Co. Ltd.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4401. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Wang, T.W. Mittag, S.M. Podos, T. Yokoyama; Effect of CS-088, an Angiotensin AT1 Receptor Antagonist, on Intraocular Pressure (IOP) in Glaucomatous Monkey Eyes . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4401.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: CS-088, an angiotensin AT1 receptor antagonist, reduces IOP in rabbits. This study evaluates the effect of topical application of 2% and 4 % CS-088 on IOP in monkey eyes with laser-induced unilateral glaucoma. Methods: A multiple-dose study was performed in 8 glaucomatous monkey eyes. One 50µl drop of CS-088, 2% or 4 %, was applied topically to the glaucomatous eye at 9:30 a.m. and 3:30 p.m. for 5 consecutive days. IOP was measured hourly for 6 hrs beginning at 9:30 a.m. for one day baseline, one vehicle-treated day, and 5 days of treatment with CS-088. The washout period between tests done on the same animal was at least 2 weeks. Results: Twice daily administration of 2% CS-088 for 5 days did not reduce the IOP until the third dose on day 2 of the treatment regimen. A significant (p<0.02) reduction of IOP occurred beginning 1 hour after the third dose which lasted for 3 hrs. The maximum reduction of IOP was 5.3 ± 0.8 (mean ± SEM) mmHg (15%) (p<0.001), with the longest duration of IOP reduction of at least 6 hrs after dosing on day 5. The 4% dose of CS-088 reduced (p<0.05) IOP from 1 hr to 5 hrs after the first dose. The maximum reduction of IOP was 6.9 ± 1.0 mmHg (20%) (p<0.001), with the longest duration of IOP reduction of at least 18 hrs after administration on day 5. Both 2% and 4 % CS-088 showed enhancement of the ocular hypotensive effect with repeated dosing. 4% CS-088 produced greater (p<0.05) IOP reduction with longer duration of action than 2%. Conclusion: Topically applied CS-088, a new antagonist drug at the angiotensin AT1 receptor, reduced IOP in glaucomatous monkey eyes in a dose- dependent manner.

Keywords: drug toxicity/drug effects • intraocular pressure • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×